NCT04056182View on ClinicalTrials.gov

Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

January 29, 2021

Study Completion Date

January 29, 2021

Conditions
Opioid-use Disorder
Interventions
DRUG

Lofexidine 0.18 MG

Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.

Trial Locations (1)

10019

STARS/NYSPI-Columbia University, New York

All Listed Sponsors
collaborator

USWM, LLC (dba US WorldMeds)

INDUSTRY

lead

New York State Psychiatric Institute

OTHER

NCT04056182 - Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment | Biotech Hunter | Biotech Hunter